Geron Corporation (GERN)

NASDAQ: GERN · IEX Real-Time Price · USD
1.46
-0.04 (-2.67%)
Jun 29, 2022 12:23 PM EDT - Market open
-2.67%
Market Cap 551.07M
Revenue (ttm) 1.38M
Net Income (ttm) -118.39M
Shares Out 377.45M
EPS (ttm) -0.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 705,253
Open 1.49
Previous Close 1.50
Day's Range 1.41 - 1.51
52-Week Range 0.99 - 1.74
Beta 0.99
Analysts Buy
Price Target 4.08 (+179.5%)
Earnings Date Aug 15, 2022

About GERN

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquarte... [Read more...]

Industry Biotechnology
IPO Date Jun 30, 1996
CEO John Scarlett
Employees 69
Stock Exchange NASDAQ
Ticker Symbol GERN
Full Company Profile

Financial Performance

In 2021, Geron's revenue was $1.39 million, an increase of 450.59% compared to the previous year's $253,000. Losses were -$116.11 million, 53.6% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for GERN stock is "Buy." The 12-month stock price forecast is 4.08, which is an increase of 179.45% from the latest price.

Price Target
$4.08
(179.45% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Trending Penny Stocks For Your Watchlist Next Month

Here are three penny stocks to watch this week The post Trending Penny Stocks For Your Watchlist Next Month  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols: SBEVVLON

Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 70,000 shares of Geron common stock as ...

Geron Corporation Announces Appointment of Faye Feller, M.D. to Chief Medical Officer and Transition of Aleksandra Ri...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Faye Feller, M.D., to Executive Vice President...

4 Biotech Stocks With Bright Prospects to Buy Amid Recovery

New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position ALKS, GERN, IMCR ...

Other symbols: ALKSBLUIMCR

Has Geron (GERN) Outpaced Other Medical Stocks This Year?

Here is how Geron (GERN) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 327,400 shares of Geron common stock as ...

Geron to Present at the H.C. Wainwright Global Investment Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies...

Why Geron Stock Is Soaring Today

Investors are reacting positively to the company's Q1 update.

Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates

Geron (GERN) delivered earnings and revenue surprises of 18.18% and 23%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Geron Corporation Reports First Quarter 2022 Financial Results

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic...

Geron to Announce First Quarter 2022 Financial Results on May 9, 2022

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that it will release its first quarter 2022 financial results after the market closes on Monday, May 9, 2022 via pr...

3 of the Fastest-Growing Stocks on the Planet Through 2026

These stocks are expected to grow their sales by 26,519% to 100,236% over the next five years.

Other symbols: RIVNVXRT

Geron to Present at the 21st Annual Needham Virtual Healthcare Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies...

Geron Corporation Announces the Closing of its Public Offering of Common Stock and Warrants

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the closing of its previously announced underwritten public offer...

Why Geron's Shares Rose 23.4% on Wednesday

The late clinical-stage biopharmaceutical company is raising money through a stock offering.

Hot Penny Stocks That Investors Are Watching Right Now

Which penny stocks are you watching right now? The post Hot Penny Stocks That Investors Are Watching Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols: MULNRMO

Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?

Penny stocks are a hot subject today with several of the top companies in the market seeing major gains on Wednesday and we know why! The post Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GER...

Other symbols: ADGIDRCTNAOVSNOAVYNT

Geron Corporation Announces the Pricing of its Public Offering of Common Stock and Warrants

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of its previously announced underwritten public offer...

Geron Corporation Announces Proposed Public Offering of Common Stock and Warrants

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock, or ...

Best Penny Stocks To Buy? 4 To Watch Now With Unusual Options Activity

Unusual options activity places these penny stocks in the hot seat. The post Best Penny Stocks To Buy?

Other symbols: MULNTELLVEON

Geron Corporation Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Milestones

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Milestones

Geron to Announce Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron to Announce Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

Geron to Present at the B. Riley Securities Virtual Oncology Investor Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron to Present at the B. Riley Securities Virtual Oncology Investor Conference

Geron to Present at the H.C. Wainwright BioConnect Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron to Present at the H.C. Wainwright BioConnect Conference

Geron Reports Presentations at American Society of Hematology Annual Meeting

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Reports Presentations at American Society of Hematology Annual Meeting